Breast milk jaundice. Neonatal jaundice from breast milk inhibitor
Conditions
Interventions
Intervention 1: Intervention group:
Intervention group includes 40 neonates with breast milk jaundice that treat with phototherapy (home or hospital) and URSODEOXYCHOLIC ACID 10 mg/kg/day (CAPSULE OR
Treatment - Drugs
Placebo
Intervention group:
Intervention group includes 40 neonates with breast milk jaundice that treat with phototherapy (home or hospital) and URSODEOXYCHOLIC ACID 10 mg/kg/day (CAPSULE ORAL 300 mg) oral
Control group:
The control groups include 40 infants who receiving placebo (distilled water) and phototherapy (home or hospital). Total bilirubin level is measured 12, 24 and 48 hours after photother
Sponsors
Vice chancellor for research of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
7 Days to 1 Months
Inclusion criteria
Inclusion criteria: Inclusion criteria: birth weights 2500 to 4000 gram; being exclusively breastfed; gestational age of 38 to 41 weeks; age more than 7 days old; total bilirubin level of 14 to 20 mg/dL; direct bilirubin level less than 2 mg/dL. Exclusion criteria: infants with ABO and RH incompatibility; glucose 6-phosphate dehydrogenase deficiency; direct hyperbilirubinemia; septicemia; diseases leading to hyperbilirubinemia (Crigler-Najjar syndrome, gilbert syndrome, hypothyroidism and hyperthyroidism, liver diseases, premature neonates and the infants of diabetic mothers)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total bilirubin level. Timepoint: Before intervention, 12, 24 and 48 hours after intervention. Method of measurement: mg/dl. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Nasri Lari
Shiraz University of Medical Sciences
Outcome results
None listed